← Back to Vital Edge Science
← Back to Vital Edge Science Compound Comparison Tool

How are these compounds
scientifically different?

Compare mechanisms, targets, research profiles and pharmacokinetics for up to 4 compounds side by side. This maps what is scientifically known — it does not tell you which compound to choose.

This is a scientific comparison, not a recommendation. It does not answer "which should I take?" — for potential combination-specific considerations, see the Interaction Checker; for regulatory/clinical-development history, see the Research Status Explorer.

Cagrilintide × Retatrutide × Tirzepatide × Semaglutide × 4 of 4 selected View comparison

Cagrilintide

Long-acting amylin analogue

Remove
VS

Retatrutide

Triple receptor agonist

Remove
VS

Tirzepatide

Dual incretin receptor agonist

Remove
VS

Semaglutide

GLP-1 receptor agonist

Remove

Target & Mechanism Comparison

Primary molecular targets for each selected compound, drawn directly from each compound's structured scientific record. Not every compound has a single conventional receptor target — where that's the case, its differentiating mechanism is noted below instead.

← Scroll to see all compounds →

Target CagrilintideRetatrutideTirzepatideSemaglutide
✓ — — —
— ✓ ✓ ✓
— ✓ ✓ —
— ✓ — —

What These Compounds Share

Shared by a subset (not all)

Retatrutide + Semaglutide + Tirzepatide also share: GLP-1R

Retatrutide + Tirzepatide also share: GIPR

Shared research line

All selected compounds are catalogued under Metabolic.

Shared pathway tags
Metabolic
Shared research areas
Obesity

Key Differences

Cagrilintide AMYLIN is a direct target of Cagrilintide that none of the other selected compounds share. Acts through the amylin system rather than GLP-1/GIP/glucagon receptor signalling.
Retatrutide GCGR is a direct target of Retatrutide that none of the other selected compounds share. Only current Vital Edge compound combining GLP-1, GIP and glucagon receptor agonism.
Tirzepatide Shares its entire target profile with at least one other compound here — no single receptor sets it apart on its own. Combines GIP and GLP-1 receptor agonism without the glucagon-receptor component of retatrutide.
Semaglutide Shares its entire target profile with at least one other compound here — no single receptor sets it apart on its own. Selective GLP-1 receptor agonism compared with tirzepatide and retatrutide's multi-receptor pharmacology.

Compound Detail

Cagrilintide
What is it?
A long-acting version of a natural hormone (amylin) that works alongside insulin to control appetite.
What are people researching/using it for?
Mainly studied for weight loss, often alongside GLP-1 medications.
Other uses being trialed
Combination therapy research alongside semaglutide/tirzepatide for obesity
Worth knowing
Often studied in combination with GLP-1 agonists rather than as a standalone agent.

Simplified for general understanding. Switch to "Full science" above for the complete research-level detail, targets, pharmacokinetics and sources.

Identity
What is it?
Long-acting amylin analogue investigated for effects on satiety, food intake and metabolic physiology.
Acylated peptide analogue · Synthetic analogue
Primary Targets & Biological System
Amylin signalling

Tap a target above for a plain-language explanation.

Mechanism & Research Profile
How does it work?
A long-acting analogue of amylin, a hormone co-released with insulin from the pancreas after eating. Amylin receptor activation is associated with slowed gastric emptying and central signalling that promotes satiety, working through a mechanism distinct from -- but often studied alongside -- the incretin pathway that GLP-1/GIP agonists use. Because amylin and GLP-1 signalling act on different receptor systems, cagrilintide is frequently investigated in combination with GLP-1 agonists rather than as a mechanistic substitute for them.
Research Areas
ObesityAppetiteSatietyEnergy intakeMetabolic research
Research Profile
Human administration: Available Preclinical: Available
Pharmacokinetics
159-195 hours (roughly 6.6-8.1 days), dose-dependent
Reported in a randomized Phase 1b trial (0.16-4.5 mg SC weekly doses, co-administered with semaglutide 2.4 mg); median Tmax 24-72 h, exposure proportional to dose.
Research Routes
Subcutaneous (descriptive only — not administration or dosing guidance)
Key Differentiator
Acts through the amylin system rather than GLP-1/GIP/glucagon receptor signalling.
Considerations
Research Limitations
Often studied in combination with GLP-1 agonists rather than as a standalone agent.
Availability & Sources
Current Vital Edge Testing
No current batch testing on file yet.
Available As (Vital Edge Science)
Cagrilintide · A$159.95 A$179.95
Browse products →
View Research Sources (1) →
Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial
The Lancet, 2021 · Human Human · 95 exposed adults (96 randomized), phase 1b multiple-ascending-dose trial, BMI 27-39.9 · Subcutaneous, once weekly · PMID 33894838 · DOI 10.1016/S0140-6736(21)00845-X

Half-life 159-195h, median Tmax 24-72h, exposure proportional to dose; did not affect semaglutide exposure/elimination.

Supports: human_half_life

Retatrutide
What is it?
A lab-made peptide designed to activate three metabolic hormone receptors at once (GLP-1, GIP and glucagon) to help the body manage blood sugar, appetite and energy use.
What are people researching/using it for?
Mainly researched for weight loss and improving blood sugar control.
Other uses being trialed
Type 2 diabetesFatty liver disease
Worth knowing
Registrational trials are ongoing; long-term outcome data beyond current trial durations is not yet available.

Simplified for general understanding. Switch to "Full science" above for the complete research-level detail, targets, pharmacokinetics and sources.

Identity
What is it?
A single peptide engineered to activate GIP, GLP-1 and glucagon receptors simultaneously.
Synthetic acylated peptide · Synthetic analogue
Also known as: LY3437943
Primary Targets & Biological System
Incretin / metabolic / glucagon signalling

Tap a target above for a plain-language explanation.

Mechanism & Research Profile
How does it work?
A single peptide engineered to activate three receptors at once: GLP-1R and GIPR (the two incretin receptors that respond to nutrient intake, central to how the body regulates insulin secretion and appetite) plus GCGR, the glucagon receptor -- usually associated with raising blood sugar and increasing energy expenditure rather than lowering it. Combining incretin agonism with glucagon-receptor agonism is the specific pharmacological rationale distinguishing retatrutide from single- or dual-receptor agonists: in Phase 2 human trials this combination was associated with reductions in body weight and improved glucose regulation. The relative contribution of the GCGR component specifically, versus the shared GLP-1R/GIPR activity, has not been isolated in human studies to date.
Research Areas
ObesityEnergy balanceGlucose metabolismType 2 diabetesMetabolic diseaseHepatic/metabolic outcomes
Research Profile
Human administration: Extensive Human observational: Available Preclinical: Available
Pharmacokinetics
Approximately 6 days
Research Routes
Subcutaneous (descriptive only — not administration or dosing guidance)
Key Differentiator
Only current Vital Edge compound combining GLP-1, GIP and glucagon receptor agonism.
Considerations
Research Limitations
Registrational trials are ongoing; long-term outcome data beyond current trial durations is not yet available.
Experimental / Off-Label Research

Not an approved or established use. These are active or emerging research directions found in the literature, shown for informational context only — not a claim that this compound is approved, effective, or safe for these purposes.

Fatty liver disease (MASLD/NAFLD)
Reductions in liver fat have been reported as a secondary finding in retatrutide obesity trials -- an active research direction, not a separate approved indication.
Obstructive sleep apnea
Investigated as a downstream effect of significant weight loss rather than a direct mechanism of its own; research in this specific population is ongoing.
Availability & Sources
Current Vital Edge Testing
Batch 2 (30mg) · tested Oct 2026 · 99.834% purity, 33.22mg content Purity/ID report
Batch 1 (30mg) Purity/ID report
Available As (Vital Edge Science)
Retatrutide — 10mg · A$109.95 A$119.95 Retatrutide — 30mg · A$299.95 A$319.95
Browse products →
View Research Sources (1) →
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
New England Journal of Medicine, 2023 · Human Human · Phase 2 obesity trial participants · Subcutaneous · DOI 10.1056/NEJMoa2301972

Supports GIP/GLP-1/glucagon receptor agonism and the ~6-day half-life used on this record.

Supports: primary_targets, human_half_life, mechanism_summary

Tirzepatide
What is it?
A lab-made peptide that mimics two natural gut hormones involved in blood sugar and appetite control.
What are people researching/using it for?
Approved and studied for type 2 diabetes and weight management.
Other uses being trialed
Sleep apnea linked to obesityHeart-related metabolic research
Worth knowing
Approved for specific branded products/indications only -- research in additional populations and combinations is ongoing.

Simplified for general understanding. Switch to "Full science" above for the complete research-level detail, targets, pharmacokinetics and sources.

Identity
What is it?
Activates GIP and GLP-1 receptors, influencing glucose-dependent insulin secretion, glucagon regulation, appetite and energy intake.
Synthetic acylated peptide · Synthetic analogue
Primary Targets & Biological System
Incretin / metabolic signalling

Tap a target above for a plain-language explanation.

Mechanism & Research Profile
How does it work?
Activates both GIP and GLP-1 receptors -- the two incretin hormone receptors that respond when nutrients enter the gut, prompting the pancreas to release insulin in a glucose-dependent way (more when blood sugar is high, less when it isn't) and slowing gastric emptying, which contributes to reduced appetite. Combining both receptors' activity, rather than GLP-1R alone, is the specific mechanistic distinction from single-receptor GLP-1 agonists like semaglutide, and is what regulatory approvals for tirzepatide-based products have been built on for type 2 diabetes and weight management.
Research Areas
Type 2 diabetesObesityGlucose regulationEnergy intakeMetabolic disease
Research Profile
Human administration: Extensive Preclinical: Available
Pharmacokinetics
Approximately 5 days
Research Routes
Subcutaneous (descriptive only — not administration or dosing guidance)
Key Differentiator
Combines GIP and GLP-1 receptor agonism without the glucagon-receptor component of retatrutide.
Considerations
Research Limitations
Approved for specific branded products/indications only -- research in additional populations and combinations is ongoing.
Experimental / Off-Label Research

Not an approved or established use. These are active or emerging research directions found in the literature, shown for informational context only — not a claim that this compound is approved, effective, or safe for these purposes.

Alcohol and substance use
Dual GIP/GLP-1 agonism is being studied for effects on alcohol consumption, extending from the larger evidence base for GLP-1-only agonists like semaglutide -- early-stage relative to that body of work.
Fatty liver disease (MASLD/NAFLD)
Liver fat reduction has been an active secondary research area in tirzepatide metabolic trials.
Availability & Sources
Current Vital Edge Testing
Batch 1 · tested Oct 2026 · 99.878% purity, 35.12mg content Purity/ID report
Available As (Vital Edge Science)
Tirzepatide · A$179.95 A$199.95
Browse products →

Source review pending for this compound — no citation on file yet.

Semaglutide
What is it?
A lab-made version of a natural gut hormone (GLP-1) that helps control blood sugar and appetite.
What are people researching/using it for?
Approved and studied for type 2 diabetes and weight loss.
Other uses being trialed
Cardiovascular risk reductionKidney health in diabetes
Worth knowing
An oral formulation exists in the wider clinical literature -- this does not describe the Vital Edge research product, which is not oral.

Simplified for general understanding. Switch to "Full science" above for the complete research-level detail, targets, pharmacokinetics and sources.

Identity
What is it?
GLP-1 receptor activation influences glucose-dependent insulin secretion, glucagon secretion, appetite, caloric intake and gastric physiology.
Synthetic GLP-1 analogue · Synthetic analogue
Primary Targets & Biological System
Incretin / metabolic signalling

Tap a target above for a plain-language explanation.

Mechanism & Research Profile
How does it work?
Activates the GLP-1 receptor, mimicking the body's own GLP-1 hormone released from the gut after eating. This triggers glucose-dependent insulin release, suppresses glucagon secretion, slows gastric emptying and acts on appetite centres in the brain -- together reducing caloric intake. This single-receptor mechanism is well characterised in the human literature (including extensive regulatory trial data) and is the pharmacological basis that dual agonists like tirzepatide and triple agonists like retatrutide build additional receptor activity on top of.
Research Areas
Type 2 diabetesObesityCardiovascular outcomesMetabolic diseaseGlucose regulation
Research Profile
Human administration: Extensive Preclinical: Extensive
Pharmacokinetics
Approximately one week
Research Routes
Subcutaneous (descriptive only — not administration or dosing guidance)
Key Differentiator
Selective GLP-1 receptor agonism compared with tirzepatide and retatrutide's multi-receptor pharmacology.
Considerations
Research Limitations
An oral formulation exists in the wider clinical literature -- this does not describe the Vital Edge research product, which is not oral.
Experimental / Off-Label Research

Not an approved or established use. These are active or emerging research directions found in the literature, shown for informational context only — not a claim that this compound is approved, effective, or safe for these purposes.

Alcohol use disorder
A randomized, placebo-controlled human trial (published in JAMA Psychiatry, 2025) and the SEMALCO trial (The Lancet) have both investigated semaglutide for reducing alcohol intake in adults with alcohol use disorder, alongside real-world population data (Nature Communications, 2024). This is active, credible clinical research -- but still investigational, not an approved use.
Nicotine / smoking cessation
A systematic review and meta-analysis of randomized trials found GLP-1 agonists reduced post-cessation weight gain and showed early signals for reduced nicotine craving, attributed to blunted dopamine reward signalling. The evidence base is still described by researchers as limited, with small samples and short follow-up.
Neurodegenerative disease (Alzheimer's)
Large-scale human trials (including the EVOKE trial program) are investigating semaglutide in early Alzheimer's disease, following observational signals linking GLP-1 agonist use to lower dementia risk. Results are not yet established.
Availability & Sources
Current Vital Edge Testing
No current batch testing on file yet.
Available As (Vital Edge Science)
Semaglutide · A$94.95 A$109.95
Browse products →

Source review pending for this compound — no citation on file yet.

Common Research Comparisons

Frequently studied groupings — not recommendations.

Browse more compounds

Metabolic

5-Amino-1MQ

NNMT inhibitor

NNMTNicotinamideNAD MetabolismSmall Molecule
Rebuild

BPC-157

Gastric pentadecapeptide

GI ResearchTissue RepairAngiogenesisNO-associated
Metabolic

Cagrilintide

Long-acting amylin analogue

AmylinSatietyAppetiteMetabolic
Peak

CJC-1295

Modified GHRH analogue

GHRHRModified GRFGHIGF-1
Neuro

DSIP

Neuropeptide

Sleep ResearchNeuropeptideNeuroendocrineCNS
Rebuild

Epithalon

Synthetic tetrapeptide

Telomere ResearchTelomeraseCellular AgeingTetrapeptide
Rebuild

GHK-Cu

Copper-binding tripeptide

Copper PeptideECMFibroblastCollagen
Peak

GHRP-2

GH-releasing peptide / GH secretagogue

GHSR1aGhrelinGH SecretagogueAppetite
Rebuild

Glutathione

Endogenous antioxidant tripeptide

GSHRedoxAntioxidantOxidative Stress
Metabolic

HCG

Glycoprotein hormone

LHCGRReproductive AxisGonadalEndocrine
Reference

IGF-1 LR3

IGF-1 receptor agonist (engineered analogue)

IGF1RGrowth FactorPI3K/AKTRAS/MAPK
Peak

Ipamorelin

GH secretagogue

GHSR1aGH SecretagogueGhrelin PathwayGH
Enhance

Kisspeptin-10

Kisspeptin fragment

KISS1RGnRHLHFSH
Rebuild

KPV

α-MSH-derived tripeptide

KPVα-MSH FragmentInflammationIL-1-associated
Enhance

Melanotan I

α-MSH analogue

MC1RMelanocortinPigmentationα-MSH Analogue
Enhance

Melanotan II

Cyclic melanocortin agonist

MelanocortinMC ReceptorsPigmentationCyclic Peptide
Metabolic

MOTS-c

Mitochondrial-derived peptide

MitochondrialAMPK-associatedMetabolicExercise Biology
Metabolic

NAD+

Cellular redox cofactor

NAD+RedoxCellular EnergySirtuins
Enhance

PT-141

Cyclic melanocortin receptor agonist

MelanocortinMC4R-associatedCNSSexual Response
Metabolic

Retatrutide

Triple receptor agonist

GLP-1RGIPRGCGRIncretin
Reference

rHGH (Somatropin)

Growth hormone receptor agonist

GHRIGF-1Growth HormonePituitary-independent
Neuro

Selank

Synthetic tuftsin analogue

Tuftsin AnalogueCNSStress ResearchNeurotransmitter Research
Metabolic

Semaglutide

GLP-1 receptor agonist

GLP-1RIncretinMetabolicGlucose
Neuro

Semax

Synthetic ACTH-fragment analogue

ACTH FragmentNeurotrophinBDNF-associatedCNS
Peak

Sermorelin

GHRH fragment analogue

GHRHRGHRH(1-29)PituitaryGH
Rebuild

SS-31

Mitochondria-targeting tetrapeptide

MitochondriaCardiolipinInner Mitochondrial MembraneBioenergetics
Peak

Tesamorelin

Stabilised GHRH analogue

GHRHRGHIGF-1Pituitary
Rebuild

Thymosin Alpha-1

Thymic peptide

ImmuneT CellsTLR-associatedInnate Immunity
Rebuild

Thymosin Beta-4 (TB-4)

Thymosin Beta-4

Thymosin Beta-4Actin BiologyCell MigrationRepair Research
Metabolic

Tirzepatide

Dual incretin receptor agonist

GIPRGLP-1RDual AgonistIncretin

Choose a compound

Metabolic

5-Amino-1MQ

NNMT inhibitor

NNMTNicotinamideNAD MetabolismSmall Molecule
Rebuild

BPC-157

Gastric pentadecapeptide

GI ResearchTissue RepairAngiogenesisNO-associated
Metabolic

Cagrilintide

Long-acting amylin analogue

AmylinSatietyAppetiteMetabolic
Peak

CJC-1295

Modified GHRH analogue

GHRHRModified GRFGHIGF-1
Neuro

DSIP

Neuropeptide

Sleep ResearchNeuropeptideNeuroendocrineCNS
Rebuild

Epithalon

Synthetic tetrapeptide

Telomere ResearchTelomeraseCellular AgeingTetrapeptide
Rebuild

GHK-Cu

Copper-binding tripeptide

Copper PeptideECMFibroblastCollagen
Peak

GHRP-2

GH-releasing peptide / GH secretagogue

GHSR1aGhrelinGH SecretagogueAppetite
Rebuild

Glutathione

Endogenous antioxidant tripeptide

GSHRedoxAntioxidantOxidative Stress
Metabolic

HCG

Glycoprotein hormone

LHCGRReproductive AxisGonadalEndocrine
Reference

IGF-1 LR3

IGF-1 receptor agonist (engineered analogue)

IGF1RGrowth FactorPI3K/AKTRAS/MAPK
Peak

Ipamorelin

GH secretagogue

GHSR1aGH SecretagogueGhrelin PathwayGH
Enhance

Kisspeptin-10

Kisspeptin fragment

KISS1RGnRHLHFSH
Rebuild

KPV

α-MSH-derived tripeptide

KPVα-MSH FragmentInflammationIL-1-associated
Enhance

Melanotan I

α-MSH analogue

MC1RMelanocortinPigmentationα-MSH Analogue
Enhance

Melanotan II

Cyclic melanocortin agonist

MelanocortinMC ReceptorsPigmentationCyclic Peptide
Metabolic

MOTS-c

Mitochondrial-derived peptide

MitochondrialAMPK-associatedMetabolicExercise Biology
Metabolic

NAD+

Cellular redox cofactor

NAD+RedoxCellular EnergySirtuins
Enhance

PT-141

Cyclic melanocortin receptor agonist

MelanocortinMC4R-associatedCNSSexual Response
Metabolic

Retatrutide

Triple receptor agonist

GLP-1RGIPRGCGRIncretin
Reference

rHGH (Somatropin)

Growth hormone receptor agonist

GHRIGF-1Growth HormonePituitary-independent
Neuro

Selank

Synthetic tuftsin analogue

Tuftsin AnalogueCNSStress ResearchNeurotransmitter Research
Metabolic

Semaglutide

GLP-1 receptor agonist

GLP-1RIncretinMetabolicGlucose
Neuro

Semax

Synthetic ACTH-fragment analogue

ACTH FragmentNeurotrophinBDNF-associatedCNS
Peak

Sermorelin

GHRH fragment analogue

GHRHRGHRH(1-29)PituitaryGH
Rebuild

SS-31

Mitochondria-targeting tetrapeptide

MitochondriaCardiolipinInner Mitochondrial MembraneBioenergetics
Peak

Tesamorelin

Stabilised GHRH analogue

GHRHRGHIGF-1Pituitary
Rebuild

Thymosin Alpha-1

Thymic peptide

ImmuneT CellsTLR-associatedInnate Immunity
Rebuild

Thymosin Beta-4 (TB-4)

Thymosin Beta-4

Thymosin Beta-4Actin BiologyCell MigrationRepair Research
Metabolic

Tirzepatide

Dual incretin receptor agonist

GIPRGLP-1RDual AgonistIncretin

Simplified for general understanding — see this compound's "How does it work?" section for the full research-level description.